- Titre
- Adjuvant Gemcitabine Alone Versus Gemcitabine-Based Chemoradiotherapy After Curative Resection for Pancreatic Cancer: A Randomized EORTC-40013-22012/FFCD-9203/ GERCOR Phase II Study
- Créateurs - sans rôle
- Jean-Luc VAN LAETHEM - Erasme University Hospital, Brussels, BelgiumPascal Hammel - Erasme University Hospital, Brussels, BelgiumLaurence Collette - Universitair Ziekenhuis BrusselVolker Budach - Erasme University Hospital, Brussels, BelgiumManfred Lutz - Erasme University Hospital, Brussels, BelgiumEric VAN CUTSEM - Universitair Ziekenhuis BrusselKarin Haustermans - Universitair Ziekenhuis BrusselFrançoise Mornex - Erasme University Hospital, Brussels, BelgiumDavid Azria - Erasme University Hospital, Brussels, BelgiumGeertjan VAN TIENHOVEN - Erasme University Hospital, Brussels, BelgiumPhilippe Vergauwe - Erasme University Hospital, Brussels, BelgiumMarc Peeters - Erasme University Hospital, Brussels, BelgiumMarc Polus - Erasme University Hospital, Brussels, BelgiumMichel Praet - Erasme University Hospital, Brussels, BelgiumMurielle Mauer - Universitair Ziekenhuis Brussel
- Détails de publication
- Journal of clinical oncology, Vol.28(29), pp.4450-4456
- Éditeur
- American Society of Clinical Oncology
- Nombre de pages
- 7
- Identifiants
- 99141145609311
- Unité académique
- Institut de Recherche en Cancérologie de Montpellier - IRCM
- Langue
- English
- Type de ressource
- Journal article
Article de revue
Adjuvant Gemcitabine Alone Versus Gemcitabine-Based Chemoradiotherapy After Curative Resection for Pancreatic Cancer: A Randomized EORTC-40013-22012/FFCD-9203/ GERCOR Phase II Study
Journal of clinical oncology, Vol.28(29), pp.4450-4456
10/10/2010
PMID: 20837948
Indicateurs
1 Consultations de la notice